X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
humans (16) 16
female (13) 13
middle aged (13) 13
male (12) 12
aged (9) 9
adult (8) 8
clinical trials (6) 6
treatment outcome (6) 6
hepatitis c, chronic - drug therapy (5) 5
antiviral agents - therapeutic use (4) 4
benzimidazoles - therapeutic use (4) 4
drug therapy, combination (4) 4
interferon (4) 4
oligopeptides - therapeutic use (4) 4
patients (4) 4
peripheral vascular disease (4) 4
research (4) 4
therapy (4) 4
thiazoles - therapeutic use (4) 4
young adult (4) 4
abridged index medicus (3) 3
aged, 80 and over (3) 3
antiviral agents - adverse effects (3) 3
benzimidazoles - adverse effects (3) 3
bi 207127 (3) 3
biomarkers (3) 3
brain ischemia - epidemiology (3) 3
drug therapy (3) 3
efficacy (3) 3
extended-release dipyridamole (3) 3
gastroenterology & hepatology (3) 3
gastroenterology and hepatology (3) 3
hepacivirus - genetics (3) 3
hepatitis (3) 3
hepatitis c (3) 3
hepatitis c, chronic - genetics (3) 3
hepatitis c, chronic - virology (3) 3
hepatitis-c (3) 3
hiv (3) 3
hiv-1-infected patients (3) 3
oligopeptides - adverse effects (3) 3
pharmacology & pharmacy (3) 3
protease inhibitor (3) 3
protease inhibitors (3) 3
recurrence (3) 3
ribavirin (3) 3
risk (3) 3
risk factors (3) 3
safety (3) 3
stroke - epidemiology (3) 3
studies (3) 3
telmisartan (3) 3
thiazoles - adverse effects (3) 3
acrylates - adverse effects (2) 2
acrylates - therapeutic use (2) 2
adolescent (2) 2
analysis (2) 2
angiotensin-converting enzyme inhibitors - therapeutic use (2) 2
antineoplastic agents - therapeutic use (2) 2
antiviral agents (2) 2
autoantibodies (2) 2
azepines - adverse effects (2) 2
azepines - blood (2) 2
azepines - pharmacokinetics (2) 2
b-cells (2) 2
benzimidazoles - administration & dosage (2) 2
benzoates - therapeutic use (2) 2
bioavailability (2) 2
biopsy (2) 2
brain ischemia - complications (2) 2
brain ischemia - prevention & control (2) 2
care and treatment (2) 2
clinical neurology (2) 2
clopidogrel (2) 2
combination (2) 2
dendritic cells (2) 2
disease (2) 2
dosage and administration (2) 2
double-blind (2) 2
double-blind method (2) 2
drug dosages (2) 2
drug interactions (2) 2
endoscopy (2) 2
follow-up studies (2) 2
gastroenterology (2) 2
genotype (2) 2
genotype & phenotype (2) 2
genotypes (2) 2
half-life (2) 2
hepacivirus - drug effects (2) 2
hepatitis c virus (2) 2
hiv protease inhibitors - administration & dosage (2) 2
hiv protease inhibitors - adverse effects (2) 2
hiv protease inhibitors - blood (2) 2
hiv protease inhibitors - pharmacokinetics (2) 2
human immunodeficiency virus--hiv (2) 2
immunodeficiency-virus-infection (2) 2
infection (2) 2
infections (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 7, pp. 630 - 639
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 6/2012, Volume 133, Issue 3, pp. 1057 - 1065
Journal Article
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 06/2019, Volume 143, Issue 6, pp. 2158 - 2169
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2016, Volume 11, Issue 8, p. e0160668
Background & Aim The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal treatment regimens. We... 
PRECLINICAL CHARACTERIZATION | THERAPY | BI 207127 | VARIANTS | SOFOSBUVIR | MULTIDISCIPLINARY SCIENCES | INFECTION | RIBAVIRIN | INHIBITOR | HEPATITIS-C | BMS-791325 | Acrylates - therapeutic use | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Thiazoles - therapeutic use | Hepacivirus - metabolism | Oligopeptides - therapeutic use | Clinical Trials, Phase III as Topic | Protease Inhibitors - therapeutic use | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Carrier Proteins - antagonists & inhibitors | Viral Nonstructural Proteins - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Mutation - genetics | Polymorphism, Genetic - drug effects | Carrier Proteins - genetics | Carrier Proteins - metabolism | Drug Resistance, Viral - drug effects | Polymorphism, Genetic - genetics | Viral Nonstructural Proteins - metabolism | Hepatitis C, Chronic - genetics | Viral Nonstructural Proteins - antagonists & inhibitors | Clinical Trials, Phase I as Topic | Amino Acid Substitution | Clinical Trials, Phase II as Topic | Antiviral agents | Complications and side effects | Drug resistance in microorganisms | Proteases | Physiological aspects | Dosage and administration | Genetic aspects | Research | Hepatitis C | Drug therapy | Clinical trials | Amino acids | Viruses | Infections | Ribavirin | Disease resistance | Hepatitis | Genotype & phenotype | Consolidation | Protease | Gastroenterology | Genotypes | Alanine | RNA polymerase | Patients | RNA-directed RNA polymerase | Studies | Polymerase | Inhibitors | Acids | Interferon | Hepatitis C virus | Binding sites | Polymorphism | Pharmaceuticals
Journal Article
RESPIRATORY RESEARCH, ISSN 1465-993X, 10/2019, Volume 20, Issue 1, pp. 1 - 13
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which diagnosis and management remain challenging. Defining the circulating... 
LUNG | DIAGNOSIS | Observational study | Interstitial lung diseases | RESPIRATORY SYSTEM | DISEASE | TISSUE | Proteome | Registries | SARCOIDOSIS | Research
Journal Article
Journal Article
Journal of Crohn's & colitis, ISSN 1873-9946, 2018, Volume 12, Issue 10, pp. 1170 - 1179
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 07/2011, Volume 51, Issue 7, pp. 1061 - 1070
The objective of this investigation was to evaluate the pharmacokinetic interaction of lopinavir/ritonavir (LPV/r) with BILR 355. In group A, 26 healthy... 
lopinavir | HIV | drug‐drug interaction | BILR 355 | ritonavir | nonnucleoside reverse transcriptase inhibitor | P‐glycoprotein | protease inhibitor (PI) | P-glycoprotein | drug-drug interaction | IMMUNODEFICIENCY-VIRUS-INFECTION | SAFETY | HIV-1-INFECTED PATIENTS | PROTEASE INHIBITOR | HEPATIC CYP3A | HIV-INFECTION | THERAPY | RESISTANCE | ANTIVIRAL ACTIVITY | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | Reverse Transcriptase Inhibitors - blood | Humans | Middle Aged | Half-Life | Pyridines - pharmacokinetics | Biological Availability | Male | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Pyridines - adverse effects | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Azepines - adverse effects | Ritonavir - administration & dosage | Ritonavir - blood | Lopinavir | Pyrimidinones - adverse effects | Azepines - blood | HIV Protease Inhibitors - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Pyrimidinones - blood | Azepines - pharmacokinetics | Pyrimidinones - administration & dosage | Ritonavir | Drug interactions | Physiological aspects | Dosage and administration | Reverse transcriptase inhibitors | Research | Bioavailability | Protease inhibitors | Drug dosages | Human immunodeficiency virus--HIV | Index Medicus
Journal Article